Revenue FY2025
$61.16B
Net Income
$4.23B
EPS (Basic)
$2.37
Net Margin
6.9%
ROE
-129.2%
Total Equity
$(3.27B)
Shares Out
1.77B
AbbVie Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2011–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.
Revenue & Net Income (10Y)
Margin Trends
Investor Ownership · 18 funds in our universe
FundPosition Value% of AUMQoQ ChgWeight
Torray Funds
Torray
$0.02B
2.8%
(11.7%)
Platinum Investment Management
Platinum Investment Management
$0.01B
1.9%
—
Capital Research Global Investors
Capital Research Global Investors
$7.57B
1.1%
(3.7%)
Matrix Asset Advisors
David Katz
$0.01B
0.7%
(0.3%)
Glenview Capital Management
Glenview Capital Management
$0.04B
0.6%
NEW
Adage Capital Management
Adage Capital Management
$0.40B
0.6%
+8.7%
Capital World Investors
Capital World Investors
$4.83B
0.6%
+21.1%
Alps Advisors
Alps Advisors
$0.04B
0.1%
+14.0%
Mairs & Power
Mairs & Power
$0.01B
0.1%
(1.4%)
Fairview Capital Investment Management
Fairview Capital Investment Management
$0.00B
0.1%
+3.1%
Jensen Investment Management
Jensen
$0.00B
0.0%
(0.7%)
Gardner Russo & Quinn
Thomas Russo
$0.00B
0.0%
—
Zevenbergen Capital Investments
Zevenbergen Capital Investments
$0.00B
0.0%
—
Chickasaw Capital Management
Chickasaw Capital Management
$0.00B
0.0%
NEW
Bridgewater Associates
Bridgewater Associates
$0.00B
0.0%
(61.2%)
Holocene Advisors
Holocene Advisors
$0.00B
0.0%
NEW
Dodge & Cox
Dodge & Cox
$0.00B
0.0%
—
Oakmark Funds (Harris Associates)
Bill Nygren
$0.00B
0.0%
(9.8%)
Insider Transactions
Reading stored insider transactions…